Browsing by Author "Aydin, D"
Now showing 1 - 5 of 5
Results Per Page
Sort Options
Item Investigation Of Sleep Disorders In Intensive Care NursesÇoban, S; Yilmaz, H; Ok, G; Erbüyün, K; Aydin, DObjective: The aim of this study was to investigate the sleep quality of intensive care nurses. Material and Method: Sixty volunteer intensive care, policlinic and general wards nurses working in Celal Bayar University Hospital were included as three equal groups. The sleep characteristics of all nurses were evaluated initially by subjective tests: Pittsburgh Sleep quality index and Epworth sleepiness scale, furthermore actigraph was used to investigate sleep quality objectively in all groups. Results were compared between the groups. Results: Pittsburgh index, which is a subjective sleep test, was found to be significantly higher in intensive care nurses. In intensive care nurses, the values of Actigraphic sleep parameters such as 'Actual wake time', 'Actual wake %', 'Total Activation Score', 'Fragmentation index' were significantly higher and 'Actual sleep time', 'Sleep efficiency' and 'Actual sleep %' were significantly lower, when compared with the policlinic nurses and the general wards nurses. Conclusion: The results of the present study indicate that, nursing of the critically ill patients continuously should give rise to sleep disorders in intensive care nurses.Item Neurological outcome after cardiac arrest: a prospective study of the predictive ability of prognostic biomarkers neuron-specific enolase, glial fibrillary acidic protein, S-100B, and procalcitoninOk, G; Aydin, D; Erbüyün, K; Gürsoy, C; Taneli, F; Bilge, S; Horasan, GDBackground/aim: Factors affecting neurological outcome and the usefulness of neuron-specific enolase (NSE), S-100B, glial fibrillary acidic protein (GFAP), and procalcitonin (PCT) in predicting neurological outcomes were assessed in patients who survived at least 24 h after cardiopulmonary resuscitation (CPR). Materials and methods: Thirty successfully resuscitated cardiac arrest patients were included in this prospective clinical study. The initial cardiac arrest rhythm, duration of CPR, return of spontaneous circulation time, administered doses of adrenaline, base excess, blood sugar, and hemodynamic parameters were recorded. Patients with Glasgow Outcome Scale (GOS) scores of 1-3 were defined as Group I and patients with GOS scores of 4-5 were defined as Group II. Serum NSE, GFAP, S-100B, and PCT levels were compared between the two groups shortly after CPR (hour 0) and at hours 12 and 24 of the postresuscitation period. Results: Serum S-100B was significantly higher (P = 0.009) in Group II immediately after CPR. Serum S-100B and NSE after CPR at hours 0, 12, and 24 were significantly lower in patients who survived to hospital discharge. Serum PCT at hours 12 and 24 and serum S-100B after CPR at 0, 12, and 24 h reached 94.7% sensitivity. Serum NSE, GFAP, S-100B, and PCT specificities were lower than 50%. Conclusion: In predicting neurological outcomes, serum S-100B has high sensitivity and low specificity immediately after CPR.Item Effect of Anaesthesia Methods for Regaining Daily Life Activities in Cesarean PatientsGürsoy, C; Ok, G; Aydin, D; Eser, E; Erbüyün, K; Tekin, I; Baytur, Y; Uyar, YObjective: Postpartum period is physically, socially and emotionally a difficult time for the parents and the baby to become a family. We tried to investigate how the anaesthesia method affects patients who underwent cesarean delivery, as a factor which also affects this period. Methods: Two hundred and six parturients, who underwent elective cesarean delivery in Celal Bayar University Hafsa Sultan Hospital were recruited for our study. After demographic data and anaesthesia methods were noted, an EQ-5D health survey and Katz ADL scale were evaluated face to face 24 hours postoperatively, and by telephone on the 5th postoperative day. Results: The percentage of patients who had general anaesthesia was 35.2% (n=71), while 19.8% (n=40) had epidural anaesthesia and 45% (n=91) had spinal anaesthesia. Among -these three methods, the EQ-5D health survey revealed that the outcome at postoperative 24 hours was best in epidural anaesthesia and that general anaesthesia outcome was the worst (p=0.007). The Katz ADL scale at postoperative 24. hours showed that epidural anaesthesia was better than the other methods for regaining daily life activities (p< 0.05). Conclusion: Our study showed that epidural anaesthesia had the most effective role among the methods in regaining daily life activities after elective cesarean delivery, which was demonstrated using the EQ-5D health survey and Katz ADL scale.Item Effectiveness and safety of cabazitaxel chemotherapy for metastatic castration-resistant prostatic carcinoma on Turkish patients (The Anatolian Society of Medical Oncology)Süner, A; Aydin, D; Hacioglu, MB; Dogu, GG; Imamoglu, GI; Menekse, S; Pilanci, KN; Yazici, ÖK; Koca, D; Karaagaç, M; Akyol, M; Akman, T; Ergen, S; Avci, N; Kaçan, T; Bozkurt, O; Kefeli, U; Urakçi, Z; Araz, M; Arpaci, E; Harputlu, H; Sevinç, AOBJECTIVE: Prostate cancer is among the most common cancers in males. Prostate cancer is androgen dependent in the beginning, but as time progresses, it becomes refractory to androgen deprivation treatment. At this stage, docetaxel has been used as standard treatment for years. Cabazitaxel has become the first chemotherapeutic agent which has been shown to increase survival for patients with metastatic Castrate Resistant Prostate Cancer (mCRPC) that progresses after docetaxel. Phase 3 TROPIC study demonstrated that cabazitaxel prolongs survival. PATIENTS AND METHODS: In this study, we evaluated a total of 103 patients who took cabazitaxel chemotherapy for mCRPC diagnosis in 21 centers of Turkey, retrospectively. This study included patients who progressed despite docetaxel treatments, had ECOG performance score between 0-2, and used cabazitaxel treatment. Patients received cabazitaxel 25 mg/m(2) at every 3 weeks, and prednisolone 5 mg twice a day. RESULTS: Median number of cabazitaxel cures was 5.03 (range: 1-17). Cabazitaxel response evaluation detected that 34% of the patients had a partial response, 22.3% had stable disease and 32% had a progressive disease. Grade 3-4 hematological toxicities were neutropenia (28.2%), neutropenic fever (14.5%), anemia (6.7%), and thrombocytopenia (3.8%). In our study, median progression-free survival (PFS) was 7.7 months and overall survival (OS) was 10.6 months. CONCLUSIONS: This study reflects toxicity profile of Turkish patients as a Caucasian race. We suggest that cabazitaxel is a safe and effective treatment option for mCRPC patients who progress after docetaxel. Moreover, ethnicity may play important roles both in treatment response and in toxicity profile.Item Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective studyKahraman, S; Hizal, M; Demirel, BC; Guven, DC; Gumusay, O; Uluc, BO; Bayram, E; Gulbagci, B; Yasar, A; Davarci, SE; Mocan, EE; Acar, O; Isik, D; Aydin, E; Karakas, Y; Ozcelik, M; Keser, M; Okutur, SK; Eren, O; Menekse, S; Aydin, D; Yilmaz, F; Dogan, O; Ozkanli, G; Yucel, H; Sunar, V; Aykan, MB; Ozdemir, O; Duman, BB; Keskinkilic, M; Sakalar, T; Inal, A; Karaoglanoglu, M; Aksoy, A; Er, MM; Turhal, NS; Kalkan, NO; Sendur, MANHighly selective inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6is) have emerged as a standart of care for first- and second-line therapies in combination with endocrine therapy (ET) for HR+/HER2- metastatic breast cancer (MBC) patients. It has been reported that combination therapy is more effective than ET alone and is safe in elderly patients as well as young patients. Nevertheless, elderly and very old patients with HR+/HER2-MBC treated with CDK4/6 inhibitor (CDK4/6i) combinations are relatively underrepresented in randomized controlled trials. To contribute to the literature, we investigated the real-world efficacy, factors associated with survival and the rates of adverse events (AEs) of the treatment with palbociclib or ribociclib plus ET in the HR+/HER2- MBC patient cohort over the age of 65 for age subgroups. In this retrospective study, 348 patients were divided into subgroups: 65-69 years old, 70-79 years old and 80 years and older. Median PFS (mPFS) for whole group was 18.3 (95% CI,14.3-22.3) months. There was no significant difference in mPFS between age groups (p = 0.75). The estimated median OS (mOS) was 39.5 (95% CI, 24.9-54.1) months and there was no significant difference between age groups (p = 0.15). There was a meaningfull numerical difference that did not reach statistical significance in patients who received CDK4/6i treatment as the first line for MBC. Grade 3-4 AEs were reported in 42.7% for the entire group, and neutropenia was the most common (37.3%). It can be concluded that combination therapy with palbociclib or ribociclib with an ET partner has similar efficacy and is safe among subgroups of older patients diagnosed with HR+/HER2-MBC.